Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2001-08-01
2004-03-23
Saunders, David (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S145100, C424S153100, C424S001570, C424S001650, C424S001690, C424S001730, C424S094100, C424S179100, C514S002600, C514S04400A
Reexamination Certificate
active
06709652
ABSTRACT:
TECHNICAL FIELD
The present invention relates to methods, compounds, compositions and kits useful for delivering to a target site a targeting moiety that is conjugated to one member of a ligand/anti-ligand pair. After localization and clearance of the targeting moiety conjugate, direct or indirect binding of a diagnostic or therapeutic agent conjugate at the target site occurs. Methods for radiometal labeling of biotin and for improved radiohalogenation of biotin, as well as the related compounds, are also disclosed. Also, clearing agents, anti-ligand-targeting moiety conjugates, target cell retention enhancing moieties and additional methods are set forth.
BACKGROUND OF THE INVENTION
Conventional cancer therapy is plagued by two problems. The generally attainable targeting ratio (ratio of administered dose localizing to tumor versus administered dose circulating in blood or ratio of administered dose localizing to tumor versus administered dose migrating to bone marrow) is low. Also, the absolute dose of radiation or therapeutic agent delivered to the tumor is insufficient in many cases to elicit a significant tumor response. Improvement in targeting ratio or absolute dose to tumor is sought.
SUMMARY OF THE INVENTION
The present invention is directed to diagnostic and therapeutic pretargeting methods, moieties useful therein and methods of making those moieties. Such pretargeting methods are characterized by an improved targeting ratio or increased absolute dose to the target cell sites in comparison to conventional cancer therapy.
The present invention describes chelate-biotin compounds and radiohalogenated biotin compounds useful in diagnostic and therapeutic pretargeting methods. The present invention also provides targeting moiety-ligand, such as biotin, compounds useful in diagnostic and therapeutic pretargeting methods. Selection of moieties and methodologies used to enhance internalization (of chemotherapeutic drugs, for example) or to enhance retention at the target cell surface (of radionuclides, for example) is also discussed.
In addition, the present invention provides targeting moiety-anti-ligand, such as avidin or streptavidin, compounds useful in diagnostic and therapeutic pretargeting methods. Other ligand-anti-ligand systems including the zinc finger protein-dsDNA fragment binding pair are also contemplated. Preparation and purification of such anti-ligand-targeting moiety compounds are also discussed.
The present invention also provides clearing agents to facilitate the removal of circulating targeting moiety-ligand (two-step) or targeting moiety-anti-ligand (two-step) or anti-ligand (three-step) from the mammalian recipient. Preferred clearing agents are classifiable as galactose-based and non-galactose-based. Within each category, preferable clearing agents are polymeric or protein based. Particulate agents, extracorporeal procedures and in vivo devices are also contemplated for use in the practice of the present invention.
Also, the present invention is directed to methods using streptavidin as an anti-ligand to enhance retention of radionuclide at target cell sites, with pretargeting protocols constituting one such method. More specifically, these embodiments of the present invention involve either (1) targeting moiety-streptavidin-radionuclide (with the radionuclide bound to streptavidin directly or through a chelate or linker), as well as (2) targeting moiety-biotin administered prior to streptavidin-radionuclide, or (3) biotin-radionuclide bound to a pretargeted streptavidin containing molecule.
The present invention further provides pretargeting methods employing intraarterial or other local administration of the therapeutic moiety-containing molecule to achieve greater localization thereof to artery-supplied target cell populations. Other methods of the present invention involve administration of short duration bone marrow protecting agents or vascular permeability enhancing agents prior to radionuclide-ligand molecule or radionuclide-anti-ligand molecule administration. Further, monovalent targeting moieties, such as Fv or Fab antibody fragments, are useful in the inventive pretargeting methods. Delivery of other, non-radioactive therapeutic agents, such as chemotherapeutic drugs, anti-tumor agents (e.g., cytokines) and toxins, to target cells using the pretargeting methods of the present invention is also described.
REFERENCES:
patent: 4639365 (1987-01-01), Sherry
patent: 4647447 (1987-03-01), Gries et al.
patent: 4833251 (1989-05-01), Musso et al.
patent: 4863713 (1989-09-01), Goodwin et al.
patent: 4895955 (1990-01-01), Ford et al.
patent: 4898951 (1990-02-01), Symons
patent: 5141966 (1992-08-01), Porath
patent: 5256395 (1993-10-01), Barbet et al.
patent: 5326778 (1994-07-01), Rosebrough
patent: 5482698 (1996-01-01), Griffiths
patent: 5525338 (1996-06-01), Goldenberg
patent: 5690907 (1997-11-01), Lanza
patent: 5736119 (1998-04-01), Goldenberg et al.
patent: 6120768 (2000-09-01), Griffiths et al.
patent: 251 494 (1988-01-01), None
patent: 327 365 (1989-08-01), None
patent: 451 824 (1991-10-01), None
patent: 496 074 (1992-07-01), None
patent: WO 88/08422 (1988-11-01), None
patent: WO 89/10140 (1989-11-01), None
patent: WO 90/12050 (1990-10-01), None
patent: WO 92/12730 (1992-08-01), None
patent: WO 93/15210 (1993-08-01), None
patent: WO 94/17829 (1994-08-01), None
Axworthy et al., “Antibody Pretargeting For Radioimmunotherapy: A Three-Step Approach In Tumored Nude Mice,”The Journal Of Nuclear Medicine; Proceedings Of The 39thAnnual Meeting 33:p. 880, Abstract No. 234, 1992.
Chatterjee,Cancer Immunol. Immunother. 38:75-82, 1994.
Curti,Crit. Rev. Oncol./Hematol. 14:29, 1993.
Galli et al., “A Radiopharmaceutical For The Study Of The Liver:99mTc-DTPA-ASIALO-OROSOMUCOID. II: Human Dynamic and Imaging Studies,”The Journal Of Nuclear Medicine And Allied Sciences 32:117-126, 1988.
Goldberg, CA-A Cancer Journal for Clinicians, 44:43, 1994.
Goodwin et al., “Pharmacokinetics of Biotin-Chelate Conjugates for Pretargeted Avidin-biotin Immunoscintigraphy,”J. Nucl. Med. :p. 880, Abstract No. 232, 1992.
Goodwin, “New Methods for Localizing Infection: A role for Avidin-Biotin,?”J. Nucl. Med. 33(10): 1816-1818, 1992.
Goodwin/Hnatowich, Letter to the Editor/Reply,J. Nucl. Med. 32(4): 750-751, 1991.
Green, “The Use of [14C]Biotin for Kinetic Studies and for Assay,”Biochem. J. 89:585, 1963.
Harris et al.,Tibtech 11:42, 1993.
Hnatowich et al., “Investigations of Avidin and Biotin for Imaging Applications,”J. Nucl. Med. 28(8): 1294-1302, 1987.
Jain,Scientific American 271(1): 58, 1994.
Jokiranta et al., “Biotinylation of Monoclonal Antibodies Prevents Their Ability to Activiate the Classical Pathway of Complement,”The Journal of Immunology 151(4): 1'14-2131, 1993.
Kalofonos et al., “Imaging of Tumor in Patients with Indium-111-Labeled Biotin and Streptavidin-Conjugated Antibodies: Preliminary Communications,”J. Nucl. Med. 31(11): 1791-1796, 1990.
Koch and Macke, “99m-Tc Labeled biotin conjugates in a Tumor “Pretargeting” Approach with Monoclonal Antibodies,”Angew. Chem. Intl. Ed. Engl. 31(11): 1507-1509, 1992.
Kricka et al., “Survey of Methods of Measuring Human Anti-Mouse Antibodies,” HAMA Survey Group,Clinica Chimica Acta. 215:153-163, 1993.
McMurry et al., “Covenient Synthesis of Bifunctional Tetraaza Macrocycles,”Bioconjugate Chem. 3(2): 108-117, 1992.
Osband et al.,Immunol. Today 11:193, 1990.
Paganelli et al., “Intraperitoneal Radio-Localization of Tumors Pre-Targeted by Biotinylated Monoclonal Antibodies,”Int. J. Cancer 45:1184-1189, 1990.
Paganelli et al., “Monoclonal antibody pretargetting techniques for tumor localization: the avidin-biotin system,”Nuclear Medicine Communications 12:211-234, 1991.
Renn and Meares, “Large-Scale Synthesis of Bifunctional Chelating Agent 2-(p-Nitrobenzyl)-1,4,7,10-tetraazacyclododecane-N,N′,N″,N-tetraacetic Acid, and the Determination of Its Enantiomeric Purity by Chiral Chromatography,”Bioconjugate Chem. 3(6): 563-569, 1992.
Rosario et al., “Bolton-Hunter and Biotin Derivatized Polylysine: A Ne
Gustavson Linda M.
Reno John M.
Theodore Louis J.
NeoRx Corporation
Saunders David
Seed IP Law Group
LandOfFree
Pretargeting methods and compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pretargeting methods and compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pretargeting methods and compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3190425